Initial Strategies in Advanced HCC: Case 2
Initial Strategies in Advanced HCC
June 2015
- A 62-year old female smoker with a history of alcoholism and type 2 diabetes, HTN is experiencing fatigue
- ECOG=1
- Child-Pugh A
- T bilirubin 1.4; albumin 3.8; INR 1.1; no ascites, no encephalopathy; platelets 94
- CT scan reveals one 6-cm liver mass with invasion into the right branch of the portal vein, metastatic disease involving the abdominal lymph nodes and lung
- Biopsy confirmed HCC diagnosis; poorly differentiated
- Patient admitted nonadherence to anti-hypertensive medications
- Therapy was initiated with sorafenib at 400 mg BID
- Patient experienced grade 1 HTN, fatigue, dyspepsia, grade 3 diarrhea
- Dose was reduced to 400 mg QD, antimotility agents were given
- Patient was counselled regarding diet
July 2016
- Follow-up imaging has shown stable disease
- ECOG=1
- Patient is now Child-Pugh B
Recent Videos
Related Content
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024Article
A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
